Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Ackermans & van Haaren increases its stake in Van Moer Logistics to 40%

GlobeNewswire

Dear shareholder,

Dear Madam, Dear Sir,

Ackermans & van Haaren, through its wholly owned subsidiary AvH Growth Capital, has entered into an agreement to increase its stake in Van Moer Logistics to 39.77%.

Van Moer Logistics is an integrated logistics services provider active in multimodal transport, port and inland waterway logistics, warehousing, value-added logistics, freight forwarding and on-site logistics.

Please find attached our press release.

Best regards

Ackermans & van Haaren

  1. Share Buy-back Programme – Transactions Week 42On 12 May 2026, Gabriel Holding A/S initiated a share buy-back programme. The buy-back runs from 12 May 2026 up to and including 16 March 2027. During this period, Gabriel Holding A/S may repurchase up to 94,500 shares corresponding to 5% of the share capital.
  2. Aktietilbagekøbsprogram – transaktioner uge 42Den 12. maj 2026 igangsatte Gabriel Holding A/S et aktietilbagekøbsprogram. Aktietilbagekøbet løber i perioden fra og med den 12. maj til og med den 16. marts 2027. I denne periode kan Gabriel Holding A/S tilbagekøbe op til en samlet beholdning på 94.500 egne aktier svarende til 5 % af aktiekapitalen.
  3. FinanceEgide - Half-year results at June 30, 2026: Net loss more than halved, amounting to €0.87m, Net financial debt reduced to €4.99mEgide Group reported a consolidated net loss of -€0.87m, compared with -€2.04m in the first half of 2025, and consolidated revenue of €15.20m.
  4. TelecomTPAYtpay Selected as Vodafone Qatar’s Direct Operator Billing AggregatorCompanies: VodafoneLong-standing partnership expands as tpay becomes Vodafone Qatar’s Direct Operator Billing aggregator, building on a proven track record of major digital service launches
  5. HealthcareOculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye DiseaseHigh-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
  6. OSB GROUP PLC - Transaction in Own SharesOSB GROUP PLC ISIN: GB00BLDRH360 19 October 2026